Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more
Zhejiang Ausun Pharmaceutical Co Ltd (603229) - Net Assets
Latest net assets as of September 2025: CN¥2.35 Billion CNY
Based on the latest financial reports, Zhejiang Ausun Pharmaceutical Co Ltd (603229) has net assets worth CN¥2.35 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.06 Billion) and total liabilities (CN¥713.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.35 Billion |
| % of Total Assets | 76.7% |
| Annual Growth Rate | 56.71% |
| 5-Year Change | 101.61% |
| 10-Year Change | 1107.98% |
| Growth Volatility | 68.21 |
Zhejiang Ausun Pharmaceutical Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Zhejiang Ausun Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual net assets of Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.27 Billion | +6.08% |
| 2023-12-31 | CN¥2.14 Billion | +46.57% |
| 2022-12-31 | CN¥1.46 Billion | +16.44% |
| 2021-12-31 | CN¥1.25 Billion | +11.35% |
| 2020-12-31 | CN¥1.13 Billion | +74.66% |
| 2019-12-31 | CN¥645.19 Million | +7.96% |
| 2018-12-31 | CN¥597.60 Million | +5.78% |
| 2017-12-31 | CN¥564.93 Million | +132.19% |
| 2016-12-31 | CN¥243.30 Million | +29.37% |
| 2015-12-31 | CN¥188.07 Million | +140.48% |
| 2014-12-31 | CN¥78.21 Million | +137.66% |
| 2013-12-31 | CN¥32.91 Million | +217.78% |
| 2012-12-31 | CN¥10.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Ausun Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 41048.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥872.32 Million | 38.40% |
| Common Stock | CN¥830.30 Million | 36.55% |
| Other Comprehensive Income | CN¥-832.49K | -0.04% |
| Other Components | CN¥570.10 Million | 25.09% |
| Total Equity | CN¥2.27 Billion | 100.00% |
Zhejiang Ausun Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Ausun Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BALLYS CORP. DL-01
F:358
|
$457.25 Million |
|
Zhejiang Noblelift Equip
SHG:603611
|
$457.30 Million |
|
Silex Systems Limited
OTCQX:SILXF
|
$457.36 Million |
|
FERRETTI S.P.A. O.N.
F:F3T1
|
$457.57 Million |
|
Apacer Technology Inc
TW:8271
|
$456.97 Million |
|
SEPLF
PINK:SEPLF
|
$456.96 Million |
|
KIRLOSKAR PNEUMATIC CO LTD
NSE:KIRLPNU
|
$456.82 Million |
|
DFDS A/S
OTCGREY:DFDDF
|
$456.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Ausun Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,141,576,554 to 2,271,891,202, a change of 130,314,648 (6.1%).
- Net income of 206,791,018 contributed positively to equity growth.
- Dividend payments of 84,215,258 reduced retained earnings.
- Other comprehensive income increased equity by 29,583.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥206.79 Million | +9.1% |
| Dividends Paid | CN¥84.22 Million | -3.71% |
| Other Comprehensive Income | CN¥29.58K | +0.0% |
| Other Changes | CN¥7.71 Million | +0.34% |
| Total Change | CN¥- | 6.08% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Ausun Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 76.67x to 3.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.12 | CN¥9.46 | x |
| 2013-12-31 | CN¥0.22 | CN¥9.46 | x |
| 2014-12-31 | CN¥0.50 | CN¥9.46 | x |
| 2015-12-31 | CN¥0.53 | CN¥9.46 | x |
| 2016-12-31 | CN¥0.62 | CN¥9.46 | x |
| 2017-12-31 | CN¥1.20 | CN¥9.46 | x |
| 2018-12-31 | CN¥1.12 | CN¥9.46 | x |
| 2019-12-31 | CN¥1.22 | CN¥9.46 | x |
| 2020-12-31 | CN¥2.15 | CN¥9.46 | x |
| 2021-12-31 | CN¥2.24 | CN¥9.46 | x |
| 2022-12-31 | CN¥2.60 | CN¥9.46 | x |
| 2023-12-31 | CN¥2.61 | CN¥9.46 | x |
| 2024-12-31 | CN¥2.75 | CN¥9.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Ausun Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.10%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.00%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.31x
- Recent ROE (9.10%) is below the historical average (18.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 22.15% | 3.89% | 0.48x | 11.84x | CN¥1.26 Million |
| 2013 | 47.26% | 12.86% | 0.68x | 5.43x | CN¥12.26 Million |
| 2014 | 27.49% | 10.67% | 0.77x | 3.33x | CN¥13.68 Million |
| 2015 | 32.36% | 23.17% | 0.65x | 2.14x | CN¥42.06 Million |
| 2016 | 23.56% | 28.83% | 0.45x | 1.83x | CN¥33.00 Million |
| 2017 | 9.38% | 22.07% | 0.32x | 1.31x | CN¥-3.48 Million |
| 2018 | 7.34% | 17.99% | 0.30x | 1.34x | CN¥-15.90 Million |
| 2019 | 8.74% | 18.31% | 0.35x | 1.37x | CN¥-8.13 Million |
| 2020 | 7.71% | 21.22% | 0.30x | 1.23x | CN¥-25.85 Million |
| 2021 | 11.63% | 25.62% | 0.31x | 1.47x | CN¥20.45 Million |
| 2022 | 16.11% | 30.79% | 0.33x | 1.58x | CN¥89.26 Million |
| 2023 | 11.86% | 31.09% | 0.28x | 1.38x | CN¥39.74 Million |
| 2024 | 9.10% | 26.00% | 0.27x | 1.31x | CN¥-20.40 Million |
Industry Comparison
This section compares Zhejiang Ausun Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical Co Ltd (603229) | CN¥2.35 Billion | 22.15% | 0.30x | $457.13 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |